No Longer Losing Weight on Wegovy? Here's How to Think About It

Why the scales stop moving: the biology of a semaglutide plateau

Wegovy (semaglutide 2.4mg) works by activating GLP-1 receptors that suppress appetite and slow how quickly food leaves your stomach. In the STEP 1 trial, published in the New England Journal of Medicine, participants lost an average of around 15% of body weight over 68 weeks, but that loss wasn't linear. The sharpest reductions typically happen in the first few months; by six to nine months, the rate slows for most people.

There's a straightforward reason. As body weight falls, your resting energy requirement falls with it. A lighter body burns fewer calories at rest, so the same calorie deficit that produced rapid loss earlier becomes a smaller deficit over time. If you want a fuller picture of how semaglutide supports losing weight and why the rate changes over time, that page is worth reading alongside your prescriber's advice. This is a predictable physiological response, not a signal that semaglutide has stopped being effective.

A second factor is partial adaptation. Some people find that appetite creeps back incrementally after months at the same dose, without reaching full pre-treatment levels. This is distinct from tolerance in the pharmacological sense; it's more accurately described as the body recalibrating around a sustained lower intake. The NHS medicines page for semaglutide describes how the medicine works and what to expect, it's a useful reference alongside your prescriber's advice.

The decision about dose: what's actually on the table

If you're currently below the 2.4mg weekly maintenance dose, the most clinically direct option is titration. Your prescriber can assess whether moving to the next step is appropriate given your current weight, how you've tolerated the medicine so far, and your wider health picture. Dose progression isn't automatic; it requires a clinical review, and a prescriber will weigh the benefits against any side effects you've been experiencing.

The newer 7.2mg semaglutide dose is worth knowing about in this context. The MHRA approved a dedicated single-dose 7.2mg Wegovy pen in April 2026 for adults with a BMI of 30 or above. Trial data showed average weight loss of around 20.7% over 72 weeks at this higher dose, which is meaningfully greater than the 2.4mg results. Whether this option is right for you is a clinical judgement (it isn't suitable for everyone) but if you've been on maintenance doses for some time and progress has stalled, it's a legitimate question to raise. For a broader look at how semaglutide works across its licensed doses, the semaglutide overview covers this in more depth.

It's also worth being direct about what dose changes can and can't do. A plateau after many months at 2.4mg, during which you've lost a clinically significant amount of weight, may reflect the medicine working as intended rather than under-performing. More isn't always the right move.

What you can change without touching your prescription

Lifestyle factors interact with semaglutide's effects more than many people expect. Adequate protein intake (roughly 1.2–1.6g per kilogram of body weight daily) helps preserve muscle mass during weight loss, and lean muscle raises your resting metabolic rate. If protein has slipped as overall appetite has dropped, that's something worth addressing with a dietitian.

Resistance-based activity (bodyweight exercises, weights, resistance bands) has a disproportionate effect on body composition during GLP-1 treatment compared with cardio alone. Sleep deprivation raises ghrelin, the appetite-stimulating hormone, which can partially offset the appetite suppression semaglutide provides. None of these changes replace the medicine or the clinical conversation; they add to it. The guide on losing weight on Wegovy goes deeper on lifestyle approaches alongside treatment. If you've been wondering whether you can stop losing weight on Wegovy and what drives that outcome, that page addresses the question in detail. If you've been wondering whether a different treatment might suit you better at this stage, the weight-loss treatment options page is a fair place to compare what's licensed in the UK.

Stopping Wegovy: what the evidence says happens next

This is probably the most important decision in this situation, and the evidence is unambiguous: for most people, weight returns after stopping semaglutide. The STEP 1 extension study found that participants who stopped after 68 weeks regained the majority of lost weight within a year. This doesn't mean you must stay on it indefinitely (there are valid medical and personal reasons to stop) but it means the decision deserves serious clinical thought, not a quick call made during a plateau.

NICE recommends semaglutide for a maximum of two years under TA875, which means some patients approach a natural endpoint. If you're nearing that point, your prescriber can discuss what comes next: whether tirzepatide might be considered, what a structured stopping plan looks like, or whether weight regain can be mitigated with sustained lifestyle changes. The page on maintaining weight after Wegovy covers this transition honestly. If you're wondering whether the plateau you're experiencing might mean Wegovy has genuinely stopped responding, this guide on Wegovy no longer working addresses that question directly. A conversation with our prescribers (reachable via the contact page) is the right next step if you're unsure which direction to take.